Dr. Yehia Hashad reports

BAUSCH + LOMB ANNOUNCES PHASE 2 RESULTS FOR GLAUCOMA NEUROPROTECTIVE CANDIDATE

Bausch + Lomb Corp. has released top-line results from its phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary end point of replicating visual function improvements observed in a smaller phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has decided not to advance the program in this indication as a topical eye drop.

"Success in drug development is based on a portfolio, not a single program," said Dr. Yehia Hashad, MD, executive vice-president, research and development, and chief medical officer of Bausch + Lomb. "We've intentionally built a diversified pipeline because we know innovation requires pursuing multiple scientific hypotheses simultaneously. Not every program will succeed, but every study helps us make smarter decisions about where to invest."

Bausch + Lomb acquired Whitecap Biosciences in 2025 primarily for the promise of developing a sustained-release implant for the treatment of geographic atrophy (GA). BL1107 (originally referred to as WB007) also showed intriguing clinical results -- with a small sample size -- for improving visual acuity in glaucoma patients. The company made a strategic decision to pursue both indications and will now focus solely on developing the first small-molecule sustained-release implant for GA. Bausch + Lomb expects clinical trials to begin in 2028 and will continue to collaborate on the candidate with Ripple Therapeutics, whose patented technology platform is based on a discovery that drugs can be chemically engineered into controlled-release pharmaceuticals without the use of polymers.

Pipeline momentum continues

Bausch + Lomb's portfolio reflects a deliberate strategy to diversify innovation across consumer, pharmaceuticals, surgical and vision care segments, rather than relying on any single asset or therapeutic area. This approach positions the company to generate multiple clinical, regulatory and commercial milestones over the coming years while supporting sustainable growth well into the next decade.

Study results

The randomized, double-masked, three-arm, parallel-group study enrolled 159 adults aged 18 and older with primary open-angle glaucoma or ocular hypertension. The study did not meet its primary end point, defined as change from baseline in visual field mean deviation at Day 28 (exit, Hour 2).

Key secondary end points assessing visual function, including low-luminance best-corrected visual acuity responder rates, were also not achieved. Evidence of ocular target engagement was observed, as demonstrated by meeting a secondary end point of a reduction in intraocular pressure at Day 28 (exit, Hour 2).

The safety profile was consistent with prior clinical experience with BL1107, with no new safety signals identified.

About Bausch + Lomb Corp.

Bausch + Lomb's mission is simple -- the company helps people see better to live better, all over the world. For nearly two centuries, Bausch + Lomb has evolved with the changing needs of patients and customers, and the company's commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, Bausch + Lomb is turning bold ideas into better outcomes through passion, perseverance and purpose.

We seek Safe Harbor.